FAKTOR OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 10:21:01 2024-07-11 am EDT | ||
| 53.16 EUR | +0.83% |
|
| Current month | -20.47% | ||
| 1 month | -11.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 53.16 | +0.83% |
| 24-07-10 | 52.72 | +0.36% |
| 24-07-09 | 52.53 | -10.10% |
| 24-07-08 | 58.43 | +8.20% |
| 24-07-05 | 54 | +0.54% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 10:21 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PD5N0V |
| ISIN | DE000PD5N0V2 |
| Date issued | 2021-07-16 |
| Strike | 976.2 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 71.92 € |
|---|---|
| Lowest since issue | 1.75 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- Certificat
